Eliem Therapeutics Total Current Liabilities 2021-2024 | CLYM
Eliem Therapeutics total current liabilities from 2021 to 2024. Total current liabilities can be defined as the sum of all liabilities classified as current for having maturities of less than one year.
Eliem Therapeutics Annual Total Current Liabilities (Millions of US $) |
2023 |
$3 |
2022 |
$6 |
2021 |
$6 |
2020 |
$3 |
Eliem Therapeutics Quarterly Total Current Liabilities (Millions of US $) |
2024-06-30 |
$4 |
2024-03-31 |
$3 |
2023-12-31 |
$3 |
2023-09-30 |
$3 |
2023-06-30 |
$4 |
2023-03-31 |
$5 |
2022-12-31 |
$6 |
2022-09-30 |
$6 |
2022-06-30 |
$8 |
2022-03-31 |
$7 |
2021-12-31 |
$6 |
2021-09-30 |
$6 |
2021-06-30 |
$6 |
2021-03-31 |
|
2020-12-31 |
|
2020-09-30 |
|
2020-06-30 |
|
Sector |
Industry |
Market Cap |
Revenue |
Medical |
MED-DRUGS |
$0.342B |
$0.000B |
Eliem Therapeutics Inc. is a clinical-stage biotechnology company. It focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems. Eliem Therapeutics Inc. is based in SEATTLE, United Kingdom.
|